Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects

The pharmacokinetics and tolerability of nebulized MP-376 (levofloxacin inhalation solution [Aeroquin]) were determined in cystic fibrosis (CF) subjects. Ten CF subjects received single 180-mg doses of two formulations of MP-376, followed by a multiple-dose phase of 240 mg once daily for 7 days. Ser...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Geller, David E., Flume, Patrick A., Griffith, David C., Morgan, Elizabeth, White, Dan, Loutit, Jeffery S., Dudley, Michael N.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2011
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3101414/
https://ncbi.nlm.nih.gov/pubmed/21444699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01744-10
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars